MBX BIOSCIENCES INC

MBXNASDAQ

🏆 #1384 by market capEarnings Nov 5US Equity

$488.38▲ $3.52 (+0.72%)

Simulated price

1h—

24h▲ 0.7%

7d—

14d—

30d—

1y—

🏦Market Cap

$3.18B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

No chart data available for MBX.

Trading Snapshot

Day Range: $485.82 – $496.88
52-Week Range: $9.63 – $72.64
Volume: $1.90B
Avg Volume: $2.39B
Shares Outstanding: 47.6M
Next Earnings: Oct 14, 2026

Fundamentals Snapshot

Annual Revenue: $237M
Last Q Revenue: $66M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-2.41
Dividend Yield: —

Why Investors Own MBX

✓High-growth profile — revenue up +57.0% YoY with expanding US Equity exposure.
✓Healthy economics — 38% gross margin and 8% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$237M▲ +50.8% YoY

Gross Margin (TTM)

38.3%▲ +2.4% YoY

Operating Income (TTM)

$28M▲ +50.8% YoY

Free Cash Flow (TTM)

$19M▲ +50.8% YoY

About MBX BIOSCIENCES INC

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.

🦦